Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Oertel

Showing results (141-150 of 153) with videos related to

Pageof 16
Sort By:
European Journal of Neurology|October 14, 2006
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's diseaseM Horstink, E Tolosa, U Bonuccelli, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 22, 1998
What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study GroupW Poewe, G Deuschl, A Nebe, et al.
European Journal of Neurology|October 14, 2006
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's diseaseM Horstink, E Tolosa, U Bonuccelli, et al.
Annals of the New York Academy of Sciences|February 24, 2001
Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's diseaseC Hock, A Maddalena, I Heuser, et al.
MMW Fortschritte Der Medizin|October 15, 2010
[The German Study on the Epidemiology of Parkinson's Disease with Dementia (GEPAD): more than Parkinson]H Von Reichmann, G Deuschl, O Riedel, et al.
European Journal of Neurology|March 16, 2013
No association of GBA mutations and multiple system atrophyK Srulijes, A-K Hauser, I Guella, et al.
NPJ Parkinson'S Disease|February 1, 2019
Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorderL M Chahine, A Iranzo, A Fernández-Arcos, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 10, 1999
Levodopa in the treatment of Parkinson's disease: a consensus meetingY Agid, E Ahlskog, A Albanese, et al.
European Journal of Neurology|January 3, 2013
EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's diseaseA Berardelli, G K Wenning, A Antonini, et al.
Neurology|June 30, 2012
Environmental risk factors for REM sleep behavior disorder: a multicenter case-control studyR B Postuma, J Y Montplaisir, A Pelletier, et al.
Pageof 16

Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
European Journal of Neurology|October 14, 2006
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's diseaseM Horstink, E Tolosa, U Bonuccelli, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 22, 1998
What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study GroupW Poewe, G Deuschl, A Nebe, et al.
European Journal of Neurology|October 14, 2006
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's diseaseM Horstink, E Tolosa, U Bonuccelli, et al.
Annals of the New York Academy of Sciences|February 24, 2001
Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's diseaseC Hock, A Maddalena, I Heuser, et al.
MMW Fortschritte Der Medizin|October 15, 2010
[The German Study on the Epidemiology of Parkinson's Disease with Dementia (GEPAD): more than Parkinson]H Von Reichmann, G Deuschl, O Riedel, et al.
European Journal of Neurology|March 16, 2013
No association of GBA mutations and multiple system atrophyK Srulijes, A-K Hauser, I Guella, et al.
NPJ Parkinson'S Disease|February 1, 2019
Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorderL M Chahine, A Iranzo, A Fernández-Arcos, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 10, 1999
Levodopa in the treatment of Parkinson's disease: a consensus meetingY Agid, E Ahlskog, A Albanese, et al.
European Journal of Neurology|January 3, 2013
EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's diseaseA Berardelli, G K Wenning, A Antonini, et al.
Neurology|June 30, 2012
Environmental risk factors for REM sleep behavior disorder: a multicenter case-control studyR B Postuma, J Y Montplaisir, A Pelletier, et al.
Pageof 16